Objective Patients with metabolic syndrome (MetS) are at a high risk for developing atherosclerosis and cardiovascular disease. Serum levels of chemerin have been found elevated in subjects with MetS and are associated with several cardiovascular factors. This study was undertaken to determine whether serum chemerin levels are associated with coronary artery disease (CAD) in patients with MetS. Methods A total of 112 patients with MetS (66 patients with CAD and 46 without CAD) and 52 healthy subjects who underwent coronary angiography for the evaluation of CAD were enrolled in this study. Serum levels of chemerin were measured by enzyme-linked immunosorbent assay. Results Serum chemerin levels were significantly elevated in MetS patients with CAD compared to in those without CAD and healthy subjects. MetS patients without CAD also had higher serum chemerin levels compared with healthy subjects. Multivariate logistic regression analysis revealed that serum chemerin levels were significantly associated with the presence of CAD in patients with MetS. Simple linear regression analysis showed that the serum levels of chemerin were positively correlated with body mass index (BMI), systolic blood pressure (SBP), serum triglycerides and C-reactive protein (CRP) in patients with MetS. Only BMI and CRP remained significantly associated with serum chemerin after multiple stepwise regression analysis. Conclusion Elevated serum chemerin levels could be considered as an independent predictive marker of the presence of CAD in patients with MetS.
Introduction
Metabolic syndrome (MetS) is characterized by multiple compounding factors such as abdominal obesity, insulin resistance, elevated plasma triglyceride (TG) levels, low highdensity lipoprotein cholesterol (HDL-c) levels, high blood pressure and altered glucose homeostasis. MetS is considered to be a significant risk factor for coronary artery disease (CAD) and mortality (1) . Follow-up of CAD patients with MetS reveals that these patients are at increased risk of cardiovascular morbidity (2) . Therefore, the early risk assessment of CAD in MetS patients and the development of strategies for preventing CAD are important.
Chemerin, a recently discovered adipocytokine, has been shown to regulate adipocyte differentiation and modulate the expression of adipocyte genes, such as glucose transporter-4, adiponectin and leptin, which are involved in glucose and lipid homeostasis (3) . It has been shown to be associated with components of MetS such as body mass index (BMI), serum triglycerides, blood pressure, insulin resistance and inflammatory makers (4, 5) . This indicates that chemerin may play a considerable role in MetS and might be a potential independent adipocytokine marker of MetS. In addition, obesity, hypertension, dyslipidemia and inflammation have been suggested to be associated with increased risks for CAD (6) . We then hypothesize that the levels of serum chemerin may be correlated with the development of CAD in patients with MetS.
Although association studies between serum chemerin levels and obesity, diabetes and coronary atherosclerosis have been conducted, to date, no investigation of the association of serum chemerin levels with CAD in MetS patients has been performed. Therefore, the present study was undertaken to determine the association between serum chemerin levels and the presence of CAD in MetS patients. Various clinical variables were also measured to identify factors associated with serum chemerin levels.
Materials and Methods

Patients
The study consisted of 112 consecutive patients with MetS who underwent coronary angiography for the evaluation of CAD. They were all diagnosed with MetS in accordance with the criteria established in the third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment in Asian population (Adult Treatment Panel III) as the presence of three or more of the following risk factors (7): waist circumference (WC) "80 cm in women or "90 cm in men, triglycerides (TG) !1.69 mmol/L, HDL-c !1.29 mmol/L in women or ! 1.03 mmol/L in men, blood pressure (BP) "130/85 mmHg, fasting blood glucose (FBG) "5.6 mmol/L.
CAD was defined as subjects who had angiographic evidence of stenosis >50% in at least one major coronary artery. Diabetic patients were excluded from this study to avoid the contribution of diabetes as a potential confounder. Patients with acute coronary syndromes, previously documented CAD, suspected myocarditis or pericarditis, malignant disease, active inflammatory disease or advanced renal disease were also excluded.
The control group consisted of 52 subjects who had none of the 5 criteria of MetS described above and no history of obesity, dyslipidemia, hypertension and diabetes mellitus. They have never been diagnosed with diabetes mellitus, impaired glucose tolerance or any other systemic diseases. This study was approved by the ethics committee of Tianjin Medical University, and informed consent was obtained from all participants.
Measurements
Anthropometric (height, weight and blood pressures), clinical and laboratory analysis were performed. Venous blood was collected after a minimum of 10 hours of fasting. Fasting plasma glucose, serum triglycerides (TG), serum total cholesterol (TC), HDL-C, LDL-C and C-reactive protein (CRP) were tested using an auto biochemistry instrument (Hitachi 7170, Tokyo, Japan). Plasma fasting insulin level was tested by radioimmunoassay. Serum chemerin levels were measured by an enzyme-linked immunosorbent assay (Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA). Body mass index (BMI) was calculated as weight in kilograms divided by height squared in meters (kg m -2 ). Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as insulin reading (μIU/mL) multiplied by plasma glucose level (mmol/L) and divided by 22.5.
Statistical analysis
The data are presented as means ± SD. Statistical analyses were performed using SPSS version 16.0 software. Data normality was analyzed using the Kolmogorov-Smirnov test. Biochemical variables were compared between MetS patients with CAD, those without CAD and healthy subjects using one-way ANOVA. Categorical variables were analyzed by the Chi-square tests. The treatment differences between patients with CAD and those without CAD were analyzed by Chi-square test. Univariate analysis was performed and the variables with a p<0.10, as well as pharmacological treatment factors, were then entered into a backward stepwise multivariate logistic regression model to assess the independent predictors for the presence of CAD. Simple linear regression analysis was performed to evaluate the correlation between the parameters. A multiple stepwise linear regression analysis was used to determine the contribution of various factors to serum chemerin. As serum chemerin levels were not normally distributed, logarithmic (log) transformed values were used for multiple linear regression analysis. A P-value of less than 0.05 was considered statistically significant.
Results
Baseline clinical characteristics
The clinical and laboratory characteristics of MetS patients and control subjects are presented in Table 1 . MetS group showed higher levels of BMI, SBP, HOMA-IR, serum TG and CRP, as well as lowered HDL-c levels than did control subjects. There were no significant differences in age, gender, DBP, serum TC and LDL-c levels between the two groups. There were significant differences in the levels of HOMA-IR and CRP between the MetS patients with CAD and those without CAD. No significant differences in the other clinical parameters including the treatment of statins and ACEI/ARB were observed between the two groups.
Association of serum chemerin level with CAD in MetS patients
The results indicated that the level of serum chemerin was significantly elevated in MetS patients with CAD compared with those without CAD and healthy controls. Furthermore, MetS patients without CAD also showed higher levels of serum chemerin than did healthy subjects ( P1: p value between control subjects and MetS patients without CAD.
P2: p value between control subjects and MetS patients with CAD.
P3: p value between MetS patients without CAD and those with CAD.
1.007 to 1.031; p=0.002) exhibited a trend (p<0.10) toward an association with the presence of angiographic CAD (Table 2). All of these variables were then entered into a backward stepwise multivariate logistic regression model. Multivariate logistic regression revealed that chemerin levels remained a significant and independent predictor of angiographic CAD (OR 1.021, 95% CI 1.008 to 1.035; p=0.001) ( Table 2 ).
Association of serum chemerin level with other clinical characteristics
Simple regression analyses showed that serum chemerin in MetS subjects was positively correlated with BMI, SBP, serum TG and CRP (Table 3) . Multiple stepwise regression analysis showed that only BMI (r=0.364, p<0.001) and CRP (r=0.427, p<0.001) remained significantly associated with serum chemerin.
Discussion
The results of our study revealed that MetS patients with CAD had higher serum chemerin levels than those without CAD. Elevated levels of chemerin were significantly associated with the presence of CAD in patients with MetS. In addition, serum chemerin in MetS subjects was positively correlated with BMI, SBP, serum TG and CRP. To the best of our knowledge, this is the first study to demonstrate the association of serum chemerin levels with the development of CAD in patients with MetS.
MetS is a constellation of physical and laboratory abnormalities, including hypertension, hyperglycemia, hyperlipidemia and abdominal obesity. Recent studies have also demonstrated that MetS is a significant risk factor for cardiovascular disease and mortality in the general population (8) . MetS is predicted to increase the all-cause and cardiac mortality, especially after 10 years, in nondiabetic patients undergoing coronary artery bypass grafting (9) . Therefore, predicting the risk for CAD in patients with MetS at the early stages is important for targeting prevention strategies. In recent years, serum biomarkers have emerged as important tools for prediction, diagnosis, risk stratification and therapeutic decision-making for patients with cardiovascular disease (6) . In the current study, elevated serum chemerin level was found to be an independent predictive marker of the presence of CAD in subjects with MetS. These data provide important evidence to support an additive role for chemerin to BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein.
that of traditional risk factors in the assessment of cardiovascular risk and establishment of primary prevention strategies for CAD.
The present study demonstrated that MetS patients had higher serum chemerin levels compared with healthy subjects. This agrees with other studies that also found a significant difference in serum chemerin levels between MetS patients and healthy controls (10) . These findings indicate that chemerin may be involved in the development and progression of MetS. Chemerin is clearly altered in patients with MetS, but whether such alterations significantly increase cardiovascular risk remains unknown. The present study also revealed that MetS patients with CAD had significantly higher serum chemerin levels than those without CAD. This result, however, is contradicted by another study in which no correlation of chemerin levels with the presence of coronary atherosclerotic plaques was found (11) . This discrepancy may have resulted from the differences in ethnicity between the studied populations or differences in enzyme-linked immunosorbent assay kits used. A possible explanation for the present results is that elevated chemerin levels may be a consequence of impaired cardiovascular function in patients with MetS. Chemerin may play a role in the pathogenesis of CAD in MetS patients. However, future investigations will be needed to explain the exact role of chemerin in the presence of CAD.
To determine the clinical parameters most strongly associated with serum chemerin levels in the MetS patients, a multiple stepwise linear regression test was performed. Results indicated that high chemerin levels were correlated with key MetS markers such as elevated levels of BMI, serum TG and blood pressure. This is consistent with other studies that also reported a significant association of serum chemerin levels with multiple compounding factors of MetS (3, 12, 13) . These findings indicate that chemerin may play an important role in the mechanism of MetS and might be a potential independent adipocytokine marker of MetS.
Previous studies have suggested that elevated serum chemerin levels are strongly related to inflammatory markers such as high sensitivity CRP, interleukin-6 and tumor necrosis factor-α (11, 14) , Similar results were found in the present study. Serum chemerin levels were significantly correlated with serum CRP concentrations in MetS patients. A growing body of evidence supports the idea that inflammation is involved in the initiation and progression of CAD (15) (16) (17) . CRP levels predict cardiovascular risk associated with both primary and secondary prevention of CAD (18) . The prognostic significance of CRP has been shown in apparently healthy adults without cardiovascular disease during long-term follow-up periods ( 8-10 years) (19) . The association of CRP with cardiovascular risk remains significant after adjustment for classic risk factors for CAD (20) . The potential limitations of these data merit consideration. First, this study was cross-sectional, thus, our findings should be investigated in long-term prospective studies before a causal relationship between the serum levels of chemerin and CAD in MetS patients can be established. Second, the study population was relatively small. Therefore, our results require further investigation in prospective studies with larger sample sizes. Finally, we did not assess the serum chemerin levels of patients with CAD but without MetS. Further studies are needed to show whether significant differences in the serum chemerin levels exist between patients with CAD and healthy controls.
In conclusion, this study showed that serum chemerin levels were elevated in MetS patients with CAD compared with those without CAD. Elevated serum chemerin levels are suggested to be an independent predictive marker of the presence of CAD in patients with MetS. And some therapy targeted for chemerin may reduce the incidence of CAD and mortality in MetS patients.
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